Asset profile
elecoglipron
Small molecule
Evidence outlook · registrational
Type 2 Diabetes: registrational readout pending
Entered Phase 3 on reliable signal mid-stage evidence. Registrational readout expected around 2028-04-06.
SOLSTICE (NCT06579105): Participants receiving AZD5004 or placebo were randomized and kept blinded to treatment; a semaglutide comparator arm was open-label but was not part of the primary comparison. The highest dose produced a substantially larger drop in HbA1c than placebo, meeting the trial's main goal.
Also in development:Chronic Kidney Disease · Phase 3Obesity · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
221 competitors in this universe: 49 direct rivals (same mechanism and indication), 1 same-class, 171 same-indication; 59 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Elecoglipron: this drug | Phase 3 | Small molecule | GLP-1 receptor | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lixisenatide (Adlyxin / Lyxumia) | Approved | Peptide | GLP-1 receptor | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| ASC30 | Phase 3 | Small molecule | GLP-1 receptor | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| CJC-1134-PC | Phase 3 | Peptide | GLP-1 receptor | ||
| CX11 | Phase 3 | Small molecule | GLP-1 receptor | ||
| DA-302168S | Phase 3 | Small molecule | GLP-1 receptor | ||
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | ||
| Efpeglenatide | Phase 3 | Peptide | GLP-1 receptor | ||
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) |
…and 206 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
43 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
2028 (7)
April 2028 (1)
May 2028 (2)
July 2028 (4)
What to watch
What to watch
What to watch
2029 (1)
September 2029 (1)
What to watch
2030 (1)
October 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.